FDA Denial Of Saw Palmetto Health Claim For BPH Prompts Lawsuit
This article was originally published in The Tan Sheet
Executive Summary
FDA's denial of a health claim relating to saw palmetto and benign prostatic hyperplasia violates the First Amendment, the Nutrition Labeling & Education Act (NLEA) and the Administrative Procedures Act (APA), Washington, D.C.-based Emord & Associates asserts in a suit filed Dec. 7.
You may also be interested in...
Supreme Court Urged To Deny Saw Palmetto Health Claim Review
The Supreme Court should refuse to consider the appropriateness of a proposed saw palmetto/prostatic hyperplasia health claim due to the petitioners' misinterpretation of the FD&C Act, Acting Solicitor General Paul Clemente maintains
Supreme Court Urged To Deny Saw Palmetto Health Claim Review
The Supreme Court should refuse to consider the appropriateness of a proposed saw palmetto/prostatic hyperplasia health claim due to the petitioners' misinterpretation of the FD&C Act, Acting Solicitor General Paul Clemente maintains
Supreme Court Urged To Deny Saw Palmetto Health Claim Review
The Supreme Court should refuse to consider the appropriateness of a proposed saw palmetto/prostatic hyperplasia health claim due to the petitioners' misinterpretation of the FD&C Act, Acting Solicitor General Paul Clemente maintains